Pharmathene,
Inc. Historical Press Releases

Pharmathene, Inc. Historical Press Releases

March 14, 2017
PharmAthene Reports Year-End 2016 Financial and Operational Results
ANNAPOLIS, Md. , March 14, 2017 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the year ended December 31, 2016 . Fourth quarter and subsequent operational
November 17, 2016
PharmAthene Declares $2.91 Special Cash Dividend on Common Stock
Final Payment of $83.9 Million Received from SIGA of $217 Million Total Judgment ANNAPOLIS, Md. , Nov. 17, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that its Board of Directors has declared a
November 16, 2016
PharmAthene Receives Final Payment from SIGA of $83.9 Million
- Award amount totals $217 million - ANNAPOLIS, Md. , Nov. 16, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today received a final payment from SIGA Technologies, Inc.
November 4, 2016
PharmAthene Reports Third Quarter 2016 Financial and Operational Results
ANNAPOLIS, Md. , Nov. 4, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the third quarter of 2016.  PharmAthene received $122.5 million from SIGA
September 16, 2016
PharmAthene Announces Receipt of Payments from SIGA
ANNAPOLIS, Md. , Sept. 16, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced it has received a series of payments from SIGA Technologies, Inc. totaling $90 million over the past month.  Combined with
August 25, 2016
PharmAthene Withdraws Protest Against HHS Over Anthrax Vaccine Bidding Process
ANNAPOLIS, Md. , Aug. 25, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that after discussions with the Biomedical Advanced Research and Development Authority (BARDA) the Company has withdrawn the
August 5, 2016
PharmAthene Files Protest Against HHS Over Anthrax Vaccine Bidding Process
ANNAPOLIS, Md. , Aug. 5, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today filed a formal protest against the Department of Health and Human Services , challenging its solicitation for a next-generation Anthrax
August 4, 2016
PharmAthene Reports Second Quarter 2016 Financial and Operational Results
ANNAPOLIS, Md. , Aug. 4, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the second quarter of 2016.  Under SIGA's Reorganization Plan, approved by U.S.
 

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe